ADXN Addex Therapeutics
- 9.4500
- +0.1197+1.28%
Addex Therapeutics News
Addex to Present at Bio€quity Europe 2024
Geneva, Switzerland, May 8, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at
Why H&E Equipment Services Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of H&E Equipment Services, Inc. (NASDAQ:HEES) fell sharply during Tuesday's session following mixed first-quarter results.H&E Equipment posted GAAP earnings of 71 cents per share, versus market
European Equities Traded in the US as American Depositary Receipts Decline
European equities traded in the US as American depositary receipts fell Tuesday morning, down 0.5% to 1,373.3 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by food
Why GeneDx Shares Are Trading Higher By 37%; Here Are 20 Stocks Moving Premarket
Shares of GeneDx Holdings Corp. (NASDAQ:WGS) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results and raised its FY2024 sales guid
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersCyclacel Pharmaceuticals (NASDAQ:CYCC) stock moved upwards by 50.0% to $2.04 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. GeneDx Hldgs (NASDAQ:WGS) shar
Sector Update: Health Care
Health care stocks rose late Monday afternoon, with the NYSE Health Care Index fractionally up and the Health Care Select Sector SPDR Fund (XLV) 0.1% higher. The iShares Biotechnology ETF (IBB) rose 1
Top Midday Decliners
Clever Leaves (CLVR) shares slumped nearly 61% in recent trading Monday. The company disclosed Friday its board decided to delist its securities on Nasdaq. ,Intraday trading volume was over 701,000 ve
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Clever Leaves Holdings Inc. (NASDAQ:CLVR) fell sharply during Monday's session after the company announced that it will voluntarily delist its common shares from the Nasdaq and deregister it
Addex Therapeutics Shares Plunge as Phase 2 Study of ADX71149 Falls Short of Primary Goal
Addex Therapeutics (ADXN) shares plunged 51% in recent Monday trading after the company said adjunctive administration of its investigational drug ADX71149 with levetiracetam or brivaracetam did not m
FLGC, BTOG and CAUD Among Mid-day Movers
Johnson & Johnson-Partnered Addex Therapeutics' Epilepsy Candidate Fails Mid-Stage Study, Stock Tanks
Monday, Addex Therapeutics (NASDAQ:ADXN) released top-line data from a Phase 2 epilepsy study evaluating adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with su
ImmunityBio, Aquestive Therapeutics, Clever Leaves Holdings Among Healthcare Movers
Dow Surges Over 100 Points; Domino's Pizza Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Monday.Following the market opening Monday, the Dow traded up 0.36% to 38,375.82 while the NASDAQ rose
Tech Rally Subsides as US Equity Futures Waver Pre-Bell
US equity futures were cautiously higher before Monday's opening bell, stabilizing after last week's rally fueled by upbeat earnings from the technology sector. Dow Jones Industrial Average futures we
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersDeciphera Pharmaceuticals (NASDAQ:DCPH) stock rose 71.0% to $25.05 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 billion. Koninklijke Philips (NYSE
Addex Therapeutics' Epilepsy Drug Fails Key Trial
Why Philips Shares Are Trading Higher By 37%; Here Are 20 Stocks Moving Premarket
Shares of Koninklijke Philips N.V. (NYSE:PHG) rose sharply in today's pre-market trading after reporting first-quarter results. The company also resolved the respironics personal injury and medical mo
Addex Therapeutics Announces Lack of Statistical Significance In ADX71149 Phase 2 Epilepsy Study
Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced
Addex Therapeutics Says Phase 2 Epilepsy Study Did Not Meet Primary Goal
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
Analysis
Price Target
No Data
